Other languages Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
5.21 ^USD	-2.98%		-4.58%	-48.57%

Mar. 13	Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM
Feb. 29	Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28
Editas Medicine Enters Licensing Deal With Vertex Pharmaceuticals for Cas9	Dec. 13
Editas Medicine and Vertex Pharmaceuticals Enter into Non-Exclusive License Agreement for Cas9	Dec. 13
Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology Annual Meeting And In A Company-Sponsored Webinar	Dec. 11
Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03
Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar	Nov. 02
Editas Medicine's EDIT-301 Receives US FDA's Regenerative Medicine Advanced Therapy Designation	23-10-16
Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024	23-10-10
Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer	23-09-25
Geron Appoints Michelle Robertson as Chief Financial Officer	23-09-11
Editas Medicine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02
Editas Medicine, Azzur Expand Agreement to Add New Cleanroom Space, Lab Services	23-07-27
Editas Medicine, Inc. and Azzur Cleanrooms on Demand, Azzur Group Company, Expand their Multi-Year Contract to Support Scaling of EDIT-301	23-07-27
Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer	23-07-24
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	23-06-15
Editas Medicine Prices Common Stock Offering; Shares Slump Premarket	23-06-15
Editas Medicine Prices Common Stock Offering	23-06-15
Editas Medicine Plans Share Offering; Stock Falls After-Hours	23-06-14
Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial	23-06-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Other languages

Filters